The Importance Of Readability: A Guide To Understanding Alopecia Areata Through Multilingual Online Resources

November 2024 in “ Acta Dermato Venereologica ”

Tomasz Skrzypczak, Anna Skrzypczak, Jacek C. Szepietowski

alopecia areata Janus kinase inhibitors JAK inhibitors

Studysummary This study found that online materials about alopecia areata and its treatments are generally difficult to understand, with information on JAK inhibitors being particularly challenging, highlighting a need for clearer educational resources for patients.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study evaluated the readability of 251 online articles about alopecia areata and its treatments across 5 languages, finding that the materials are generally very hard to comprehend, with an overall mean Lix score of 52 ± 8. Articles on treatments, particularly those about Janus kinase inhibitors, were even more difficult, with mean scores of 55 ± 8 and 57 ± 10, respectively. The findings emphasize the necessity for clearer patient education materials to aid informed decision-making and enhance therapeutic relationships.

View this study on medicaljournalssweden.se →

Discuss this study in the Community →

Research cited in this study

12 / 12 results

research Comparative Efficacy of Oral Janus Kinase Inhibitors and Biologics in Adult Alopecia Areata: A Systematic Review and Bayesian Network Meta-Analysis

20 citations , January 2024 in “Journal of the European Academy of Dermatology and Venereology”

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients

January 2024 in “Acta dermato-venereologica”

research Baricitinib for the Treatment of Alopecia Areata in Adults: Real-World Analysis of 36 Patients

12 citations , January 2024 in “Journal of the American Academy of Dermatology”

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

4 citations , January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review

1 citations , October 2023 in “Dermatology and therapy”

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

research Treatment Patterns for Alopecia Areata in the US

7 citations , September 2023 in “JAMA Dermatology”

This study reviewed treatment patterns for adults with alopecia areata in the US from 2015 to 2020, revealing that corticosteroids were the most common treatment, yet over two-thirds of patients were not receiving any treatment a year after diagnosis.

research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data

September 2023 in “Dermatology and Therapy”

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review

1 citations , June 2023 in “Genes”

This study highlights the genetic complexities in alopecia areata, emphasizing the role of microRNAs and their association with other immune-related diseases, which could inform targeted treatment strategies.

research Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population

75 citations , March 2023 in “JAMA Dermatology”

This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.

research Alopecia Areata: Overview and Insights from January 2018

290 citations , December 2017 in “Journal of The American Academy of Dermatology”

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

research Epidemiology and Burden of Alopecia Areata: A Systematic Review

144 citations , July 2015 in “Clinical, Cosmetic and Investigational Dermatology”

This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.

research Interventions for Alopecia Areata

164 citations , April 2008 in “Cochrane library”

This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.